Relief for Parents During RSV Season

Fred Hutch researchers confirm that infant anti-RSV therapies remain highly effective and create an early-warning system to detect viral changes that could undermine their protection
Video by Robert Hood / Fred Hutch News Service

The first thing Cassandra Simonich, MD, PhD, wants parents to know about protecting their infants during cold and flu season is that the current prevention therapies for respiratory syncytial virus, or RSV, are safe, effective and recommended.

But Simonich, a research associate at Fred Hutch Cancer Center and a pediatric infectious diseases physician at Seattle Children’s, also knows that viruses change over time and therapies that are highly effective today might be less so if the virus evolves resistance.

To improve how researchers monitor changes in RSV, she collaborated with Jesse Bloom, PhD, an evolutionary virologist at Fred Hutch.

They recently published the results of that collaboration in the journal Nature.

The study applied a technique developed in the Bloom Lab to safely investigate all the potential ways that RSV could evolve to resist these therapies.  

Subscribe to Fred Hutch News

You will receive a free monthly newsletter from us about our innovative research and compassionate care as well as updates on events and other helpful tools and tips. 

You may unsubscribe at any time.

Listen to the audio interview 

Libsyn | Spotify | Apple Podcasts | Amazon Podcasts | YouTube

The team analyzed more than 60,000 genomic sequences of the virus from all over the world sampled from people with RSV and published in public databases.

Their investigation confirmed that resistance to current therapies has arisen sporadically but remains rare. 

The team also discovered a weak link that explains why one of the two major subtypes of RSV is more susceptible to resistance mutations than the other.

Their innovative approach enables real-time surveillance for natural RSV strains with resistance mutations and provides a road map to weak links in RSV and potentially in other viruses that researchers can use to make better therapies.

Current therapies work, which requires vigilance to keep it that way

RSV is one of many viruses that causes the common cold in healthy adults but poses a greater threat to infants, older adults with weakened immune systems and people who are immunocompromised – such as when undergoing cancer treatment.

The virus remains the leading cause of infant hospitalization in the United States. Though it’s seldom fatal in the U.S. and other countries with advanced health care systems, it’s a leading cause of infant mortality globally, especially in less developed countries.

RSV vaccines are available for vulnerable adults, and a vaccinated mother can pass protective antibodies to her infant, but that approach only works in a narrow window of time.

The maternal RSV vaccine (Pfizer's Abrysvo) is given during weeks 32-36 of pregnancy, and maternal antibodies protect the baby against RSV for approximately six months after birth, according to the U.S. Centers for Disease Control and Prevention.

There is no RSV vaccine for infants, but they can receive RSV immunization with ready-made antibodies that provide immediate protection and last at least five months to see infants through the RSV season.

The American Academy of Pediatrics recommends RSV immunization for all infants under 8 months of age born during or entering their first RSV season unless they are protected by a maternal vaccination during pregnancy.

The Centers for Disease Control and Prevention recommends either nirsevimab or clesrovimab for all babies younger than 8 months born to mothers who didn’t receive a maternal RSV vaccine during pregnancy.

“It's so incredible — as a physician, as a pediatrician, and as a mom — that we now can use these things to prevent RSV disease,” Simonich said. “We know that these things are highly effective. They work really well.”

For example, the most widely used RSV antibody, nirsevimab, has demonstrated roughly 75% to 80% effectiveness against RSV-associated hospitalizations of infants and (along with maternal vaccination) has reduced infant hospitalizations in countries where it is widely used, according to the Nature study.

But viruses can evolve to escape such antibodies.

One RSV antibody failed clinical trials because of a resistant strain, and resistance mutations have popped up sporadically to nirsevimab.

“Fortunately, it's rare, but we need to be on the lookout,” Simonich said. “The field has been really diligent, and they've been really focused on monitoring RSV very closely for any signs of resistance.”

But the standard methods for keeping tabs on the evolution of the virus are slow and labor intensive, which is why Simonich turned to the Bloom Lab at Fred Hutch to try a new approach.

A safe way to build an early-warning system

Typically, researchers have found resistance mutations either by watching the virus evolve in laboratory experiments or by analyzing virus samples from patients one at a time.

“The monitoring up to this point had been kind of limited because basically there wasn't a thorough or comprehensive understanding of the impact of any viral changes that they observed without monitoring what they actually mean for the ability of these antibodies to still effectively target the virus,” Simonich said.

Over the last few years, Bloom’s team in the Basic Sciences Division has figured out a new way to get that big picture quickly by safely running thousands of experiments simultaneously to discover which possible mutations matter for virus survival and should raise an alarm if they pop up on the radar of surveillance efforts.

They call the method pseudovirus-based deep mutational scanning, which involves genetically engineering a pseudovirus that can infect a cell like the real thing, but only once. The pseudovirus cannot reproduce and spread like an actual virus, making it much safer for experimentation.

They also add some features to the pseudovirus to streamline its use for deep mutational scanning experiments that can systematically measure the effects of thousands of mutations on a virus’ ability to infect cells and escape virus-killing antibodies.

The Bloom Lab has used the method to identify mutations to the infamous “spike” protein in the virus that causes COVID-19, which have helped the virus dodge our vaccines and outrun our growing natural immunity. The lab has also used the method to safely investigate the much rarer but more deadly Nipah virus.

Working with Simonich, the lab analyzed 60,000 RSV sequences from public databases to test the effects of potential mutations to a critical molecular complex called a fusion protein, which allows the virus to glom onto a cell.

The anti-RSV antibodies work because they bind to the fusion protein and prevent it from fusing the membranes of the virus and the host cell. When it’s locked and blocked by the antibodies, the fusion protein can’t enter the host cell to infect it.

But resistance mutations to the fusion protein might interfere with the locking and blocking, which would make what is now an effective therapy less effective.

“The really nice thing about this system is that we don't ever have to use any actual RSV virus,” Simonich said.  “We just use a little piece and focus on the target of the antibody, which is the fusion protein. And so that makes it a really, really safe way to generate these comprehensive maps.”

The team used the system to measure the effect of every possible mutation on antibody effectiveness. Simonich estimated that less than 1% of RSV sequences contain resistance mutations.

“When we scored all of these sequences, we find that strains with resistance mutations are exceedingly rare,” she said.

They integrated their scoring system into Nextstrain — an open-access platform for monitoring pathogens — to create a real-time early warning system so researchers can be on the lookout for the mutations most likely to cause trouble.

The analysis confirmed that the current RSV immunization therapies are working as intended.

But when they dug deeper into the data and performed some additional experiments, they discovered a weak link in the system that RSV could exploit to evade those therapies.

Experiments reveal a weak link that viruses could exploit

The viral sequences the team analyzed included two main subtypes — RSV A and RSV B — which circulate together. The subtypes are similar in almost every way, but while resistant mutations are rare overall, they are more common in subtype B than subtype A. Nobody knew why.

“That was really confusing to the field because if you look sort of generally, nirsevimab seems to neutralize both subtypes very similarly,” Simonich said.  “They really are similar in terms of their sequence. They're similar in their structure. It was a really big question, so we really dug into this.”

The nirsevimab antibodies have two hands that both grab the fusion protein to lock and block it, but the team discovered that the hands get a tighter grip on subtype A than they do on subtype B.

Certain mutations weaken the grip of nirsevimab on both subtypes, but the effect isn’t the same because the starting grip strength is stronger on subtype A than it is on subtype B.

A single mutation may not matter much for subtype A because if it loosens the grip of one hand, the other hand is strong enough to compensate. But the same mutation matters more for subtype B because if one hand gets even weaker, the other hand can’t come to the rescue because both hands started out with a weaker grip.

And if mutations pile up, the initial weaker grip strength on subtype B can become a liability for the antibody’s ability to grab subtype A, which is how a virus can become resistant.

“We showed that, uh-oh, if two or three of these mutations accumulate, you start to see an impact in subtype A,” Simonich said. “It was important to do that because now, as surveillance is ongoing, we have even more insight as mutations accumulate over time. That was a surprising and important finding of this study.”

The discovery draws attention to previously unknown weak links in the chain that developers will want to shore up when they engineer future RSV immunization therapies. The principle may also apply to other viruses where mutations could exploit differential grip strengths.

But she wants to make sure parents understand that the RSV therapies currently available are doing what they are supposed to be doing and mutations that could undermine their effectiveness are rare, at least for now.

“These things are safe and effective and they're so important and they're so good,” she said. “We're just making sure that if there is a change, we know right away and we can pivot to an alternative.”

This work was supported by the National Institutes of Health, the Gates Foundation, a Eunice Kennedy Schriver grant and the Genomics & Bioinformatics Shared Resource of the Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium.

John Higgins

John Higgins, a staff writer at Fred Hutch Cancer Center, was an education reporter at The Seattle Times and the Akron Beacon Journal. He was a Knight Science Journalism Fellow at MIT, where he studied the emerging science of teaching. Reach him at jhiggin2@fredhutch.org or @jhigginswriter.bsky.social.

reprint-republish

Are you interested in reprinting or republishing this story? Be our guest! We want to help connect people with the information they need. We just ask that you link back to the original article, preserve the author’s byline and refrain from making edits that alter the original context. Questions? Email us at communications@fredhutch.org

Related News

All news
New horizons in infectious disease treatment and prevention in immunocompromised patients The 5th Symposium on Infectious Disease in the Immunocompromised Host emphasized new opportunities, next generation June 23, 2025
Managing mountains of genomic data Tools invented at Fred Hutch are helping researchers analyze the enormous global database of genomic sequences of the virus that causes COVID-19 to better understand how pathogens evolve and spread April 22, 2025
Going straight to the source in defense against infant RSV New anti-idiotype antibody a first step in possible strategy to build infant immunity during vulnerable window November 12, 2024

Help Us Eliminate Cancer

Every dollar counts. Please support lifesaving research today.